Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Endometrial Neoplasms 2Breast Neoplasms 2Treatment for Metastatic or Locally Advanced Cervical Cancer 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 6Cisplatin 5infigratinib 2Platinum 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2ricolinostat 1niraparib 1lenvatinib 1galactomannan 1fludarabine 1famitinib 1dostarlimab 1atezolizumab 1aldesleukin 1Taxes 1Standard of Care 1Sildenafil Citrate 1Sevoflurane 1Photochemotherapy 1Oxaliplatin 1Observation 1NVP-BKM120 1Interviews as Topic 1IMC-001 1Electroporation 1Desflurane 1Cyclophosphamide 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Cholangiocarcinoma × NVP-BKM120 × Clear all
NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡